Mechanism of arsenic carcinogenesis: An integrated approach

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 533, Issue 1-2, 2003, Pages 37-65

  Rossman, Toby G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenic; Carcinogenesis; DNA repair; Gene expression; Genomic instability; Oxidants

Indexed keywords

ARSENIC;

BLADDER CARCINOGENESIS; BLADDER CARCINOMA; DNA DAMAGE; DNA REPAIR; GENOTOXICITY; HUMAN; LUNG CARCINOGENESIS; LUNG CARCINOMA; METABOLISM; METHYLATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN CARCINOGENESIS; SKIN CARCINOMA;

ANIMALIA;

EID: 0345276611     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2003.07.009     Document Type: Review

References (299)

1. Chowdhury T.R., Basu G.K., Mandel B.K., Biswass B.K., Samanta G., Chowdhury U.K., Chandra C.R., Lodh D., Roy S.L., Saha K.C., Roy S., Kabir S., Quamruzzaman Q., Chakraborti D. Arsenic poisoning in the Ganges delta. Nature. 401:1999;545-546.
2. Simeonova P.P., Luster M.I. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms. J. Envrion. Pathol. Toxicol. Oncol. 19:2000;281-286.
3. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172:2001;249-261.
4. Rosen B.P. Biochemistry of arsenic detoxification. FEBS Lett. 529:2002;86-92.
5. Styblo M., Drobna Z., Jaspers I., Lin S., Thomas D.J. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 110:2002;767-771.
6. Hughes M.F. Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 13:2002;1-16.
7. Bode A.M., Dong Z. The paradox of arsenic: molecular mechanisms of cell transformaiton and chemoterapeutic effects. Crit. Rev. Oncol./Hematol. 42:2002;5-24.
8. Rossman T.G., Goncharova E.I., Rajah T., Wang Z. Human cells lack the inducible tolerance to arsenite seen in Chinese hamster cells. Mutat. Res. 386:1997;307-314.
9. Basu A., Mahata J., Gupta S., Giri A.K. Genetic toxicology of a paradoxical human carcinogen, arsenic: a review. Mutat. Res. 488:2001;171-194.
10. Miller W.H. Jr., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 62:2002;3893-3903.
11. Yi J., Gao F., Shi G., Li H., Wang Z., Shi X., Tang X. The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemia cells to arsenic trioxide. Apoptosis. 7:2002;209-215.
12. M.D. Pulido, A.R. Parrish, Metal-induced apoptosis: mechanisms, Mutat. Res. 233 (2003) 227-241.
13. Yih L.-H., Lee T.-C. Effects of exposure protocols on induction of kinetochore-plus and -minus micronuclei by arsenite in diploid human fibroblasts. Mutat. Res. 440:1999;75-82.
14. Barchowsky A., Roussel R.R., Klei L.R., James P.E., Ganju N., Smith K.R., Dudek E.J. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol. Appl. Pharmacol. 159:1999;65-75.
15. Huang C., Ma W.-Y., Li J., Goranson A., Dong Z. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J. Biol. Chem. 274:1999;14595-14601.
16. Vogt B., Rossman T.G. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts - a possible mechanism for arsenite's comutagenicity. Mutat. Res. 478:2001;159-168.
17. Del Razo L.M., Quintanilla-Vega B., Brambila-Colombres E., Calderon-Aranda E.S., Manno M., Albores A. Stress proteins induced by arsenic. Toxicol. Appl. Pharmacol. 177:2001;132-148.
18. T.G. Rossman, Molecular and genetic toxicology of arsenic, in: J. Rose (Ed.), Environmental Toxicology: Current Developments, Gordon and Breach Science Publishers, Amsterdam, 1998, pp. 171-187.
19. National Research Council, Arsenic in Drinking Water, National Academy Press, Washington, DC, 2000.
20. Tseng W.P., Chu H.M., How S.W., Fong J.M., Lin C.S., Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst. 40:1968;453-4635.
21. Tseng W.P. Effects and dose response relationships of skin cancer and blackfoot disease with arsenic. Environ. Health Perspect. 19:1977;109-119.
22. Borgono J.M., Vicent P., Venturino H., Infante A. Arsenic in the drinking water of the city of Antofagasta: epidemiological and clinical study before and after the installation of a treatment plant. Environ. Health Perspect. 19:1977;103-105.
23. Hopenhayn-Rich C., Biggs M.L., Smith A.H. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba Argentina. Int. Epidemiol. Assoc. 27:1998;561-569.
24. Cebrian M.E., Albores A., Aguilar M., Blakely E. Chronic arsenic poisoning in the north of Mexico. Human Toxicol. 2:1983;121-133.
25. Chen C.-J., Chen C.W., Wu M.-M., Kuo T.-L. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br. J. Cancer. 66:1992;888-892.
26. Smith A.H., Hopenhayn-Rich C., Bates M.N., Goeden H.M., Hertz-Picciotto I.H., Duggan I., Wood R., Kosnett M., Smith M.T. Cancer risk from arsenic in drinking water. Environ. Health Perspect. 97:1992;259-267.
27. IARC (International Agency for Research on Cancer). IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, vol. 23, Some Metals and Metallic Compounds, World Health Organization, Lyon, France, 1980.
28. Tinwell H., Stephens S.C., Ashby J. Arsenite as the probable active species in the human carcinogenicity of arsenic: mouse micronucleus assays on Na and K arsenite, orpiment, and Fowler's solution. Environ. Health Perspect. 95:1991;205-210.
29. Lerman S.A., Clarkson T.W., Gerson R.J. Arsenic uptake and metabolism by liver cells is dependent on arsenic oxidation state. Chem.-Biol. Interact. 45:1983;401-406.
30. Bertolero F., Pozzi G., Sabbioni E., Saffiotti U. Cellular uptake and metabolic reduction of pentavalent to trivalent arsenic as determinants of cytotoxicity and morphological transformation. Carcinogenesis. 8:1987;803-808.
31. Delnomdedieu M., Styblo M., Thomas D.J. Time dependence of acumulation of binding of inorganic and organic arsenic species in rabbit erythrocytes. Chem. Biol. Interact. 298:1995;69-83.
32. M. Styblo, L.M. Del Razo, L. Vega, D.R. Germolec, E. LeCluyse, G.A. Hamilton, W. Reed, C. Wang, W.R. Cullen, D.J. Thomas, Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells, Archives of Toxicology, Spring-Verlag, Berlin, 2000, pp. 1-17.
33. Vega L., Styblo M., Patterson R., Cullen W., Wang C., Germolec D. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol. Appl. Pharmacol. 172:2001;225-232.
34. Liu Z., Shen J., Carbrey J.M., Mukhopadhyay R., Agre P., Rosen B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. 99:2002;6053-6058.
35. Huang R.N., Lee T.C. Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol. Appl. Pharmacol. 136:1996;243-249.
36. Marafante E., Vahter M., Norin H., Envall J., Sandstrom M., Christakopoulos A., Ryhage R. Biotransformation of dimethylarsinic acid in mouse, hamster and man. J. Appl. Toxicol. 7:1987;111-117.
37. Healy S.M., Wildfang E., Zakharyan R.A., Asposhian H.V. Diversity of inorganic arsenic biotransformation. Biol. Trace Element Res. 68:1999;249-266.
38. Vahter M., Concha G. Role of metabolism in arsenic toxicity. Pharmacol. Toxicol. 89:2001;1-5.
39. Thomas D.J., Styblo M., Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 176:2001;127-144.
40. Gregus Z., Németi B. Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci. 70:2002;13-19.
41. Radabaugh T.R., Sampayo-Reyes A., Zakharyan R.A., Aposhian H.V. Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol. 15:2002;692-698.
42. Scott N., Hatlelid K.M., MacKenzie N.E., Carter D.E. Reactions of arsenic (III) and arsenic (V) species with glutathione. Chem. Res. Toxicol. 6:1993;102-106.
43. Németi B., Csanaky I., Gregus Z. Arsenate reduction in human erythrocytes - testing the role of purine nucleoside phosphorylase. Toxicol. Sci. 74:2003;22-31.
44. Lin S., Shi Q., Brent Nix F., Styblo M., Beck M.A., Herbin-Davis K.M., Hall L.L., Simeonsson J.B., Thomas D.J. A novel S-adenosyl-L-methionine: arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 277:2002;10795-10803.
45. v) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 14:2001;1051-1057.
46. Vhater M. Mechanisms of arsenic biotransformation. Toxicology. 181-182:2002;211-217.
47. Brown J.L., Ketchin K.T., George M. Dimethylarsinic acid treatment alters six different rat biochemical parameters: relevance to arsenic carcinogenesis. Terotogen. Carcinog. Mutagen. 17:1997;71-84.
48. Styblo M., Serves S.V., Cullen W.R., Thomas D.J. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol. 10:1997;27-33.
49. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., Aposhian H.V. Monomethylarsonous acid (MMIII) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163:2000;203-207.
50. Petrick J.S., Jagadish B., Mash E.A., Aposhian H.V. Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 14:2001;651-656.
51. Lin S., Cullen W.R., Thomas D.J. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem. Res. Toxicol. 12:1999;924-930.
52. Powis G., Montfort W.R. Properties and biological activities of thioredoxins. Annu. Rev. Pharmacol. Toxicol. 41:2001;261-295.
53. Wilbourne J., Haroun L., Heseltine E., Kaldor J., Partensky D., Vainio V. Response of experimental animals to human carcinogens: an analysis based upon the IARC monographs programme. Carcinogenesis. 7:1986;1853-1863.
54. Ivankovic S., Eisenbrand G., Preussmann R. Lung carcinoma induction in BD rats after single intratracheal instillation of an arsenic-containing pesticide mixture formerly used in vineyards. Int. J. Cancer. 34:1979;786-788.
55. Ishinishi N., Yamamoto A., Hisanaga A., Inamasu T. Tumorigenicity of arsenic trioxide to the lung in Syrian golden hamsters by intermittent instillations. Cancer Lett. 21:1983;141-147.
56. Pershagen G., Nordberg G., Bjorklund N.E. Carcinomas of the respiratory tract in hamsters given arsenic trioxide and/or benzo(a)pyrene by the pulmonary route. Environ. Res. 34:1984;227-241.
57. Yamamoto A., Hisanaga A., Ishinishi N. Tumorigenicity of inorganic arsenic compounds following intratracheal instillations to the lungs of hamsters. Int. J. Cancer. 40:1987;220-223.
58. Milner J.E. The effects of ingested arsenic exposure on methyl cholanthrene induced skin tumours in mice. Arch. Environ. Health. 18:1969;7-11.
59. Germolec D.R., Spalding J., Boorman G.A., Wilmer J.L., Yoshida T., Simeonova P.P., Bruccoleri A., Kayama F., Gaido K., Tennant R., Burleson F., Dong W., Lang R.W., Luster M.I. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat. Res. 386:1997;209-218.
60. Yamamoto S., Konishi Y., Matsuda T., Murai T., Shibata M., Matsui-Yuasa I., Otani S., Kuroda K., Endo G., Fukushima S. Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res. 55:1995;1271-1276.
61. Luster M.I., Wilmer J.L., Germolec D.R., Splading J., Yoshida T., Gaido K., Simeonova P.P., Burleson F.G., Bruccoleri A. Role of keratinocyte-derived cytokines in chemical toxicity. Toxicol. Lett. 82-83:1995;471-476.
62. O'Brien T.G., Megosh L.C., Gillard G., Soler A.P. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res. 57:1997;2630-2637.
63. Chen Y., Megosh L.C., Gilmour S.K., Sawicki J.A., O'Brien T.G. K6/ODC transgenic mice as a sensitive model for carcinogen identification. Toxicol. Lett. 116:2000;27-35.
64. de Gruijl F.R. Skin cancer and solar UV radiation. Eur. J Cancer. 35:1999;2003-2009.
65. Rossman T.G., Uddin A.N., Burns F.J., Bosland M. Arsenic is a cocarcinogaen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 176:2001;64-71.
66. T.G. Rossman, A.N. Uddin, F.J. Burns, Evidence that arsenite acts as a cocarcinogen in skin cancer, Toxicol. Appl. Pharmacol., 2003, in press.
67. Brash D.E., Rudolph J.A., Somon J.A., Lin A., McKenna G.J., Baden H.P., Halpern A.J., Poten J. A role for sunlight in skin cancer: UV induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 88:1991;10124-10128.
68. Ziegler A., Jonason A.S., Leffell D.J., Simon J.A., Sharma H.W., Kimmelman J., Remington Jacks T., Brash D.E. Sunburn and p53 in the onset of skin cancer. Nature. 372:1994;773-776.
69. I. Hertz-Piccioto, Interactions between arsenic and other exogenous exposures in relation to health outcomes, in: W.R. Chappell, C.O. Abernathy, R.L. Calderon (Eds.), Proceedings of the 4th International Conferences on Arsenic Exposure and Health Effects, Elsevier, Amsterdam, 2001, pp. 173-180.
70. Chiou H.-Y., Hsueh Y.-M., Liaw K.-F., Horng S.-F., Chiang M.-H., Pu Y.-S., Lin J.S.-N., Huang C.-H., Chen C.-J. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 55:1995;1296-1300.
71. Tsuda T., Babazono A., Yamamoto E., Kurumatani N., Mino Y., Ogara T., Kishi Y., Aoyama H. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am. J. Epidemiol. 141:1995;198-209.
72. Waalkes M.P., Ward J.M., Liu J., Diwan B.A. Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol. Appl. Pharmacol. 186:2003;7-17.
73. Wang Z., Dey S., Rosen B.P., Rossman T.G. Efflux mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Toxicol. Appl. Pharmacol. 137:1996;112-119.
74. Gebel T.W. Genotoxicity of arsenical compounds. Int. J. Hyg. Environ. Health. 203:2001;249-262.
75. Li J.-H., Rossman T.G. Mechanism of comutagenesis of sodium arsenite with N-methyl-N-nitrosourea. Biol. Trace Element Res. 21:1989a;373-381.
76. + V79 cell lines differ in their mutagenic response to clastogens. Mutat. Res. 304:1994;217-228.
77. Klein C.B., Su L., Snow E.T. Characterization of gpt-deletion mutations in transgenic Chinese hamster cell lines. Environ. Mol. Mutagen. 30:1997;421-428.
78. Li J.-H., Rossman T.G. Comutagenesis of sodium arsenite with ultraviolet radiation in Chinese hamster V79 cells. Biol. Met. 4:1991;197-200.
79. Moore M.M., Harrington-Brock K., Doerr C.L. Relative genotoxic potency of arsenic and its methylated metabolites. Mutat. Res. 386:1997;279-290.
80. 52 cells. Mutat. Res. 356:1996;255-0259.
81. Hei T.K., Liu S.X., Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 95:1998;8103-8107.
82. Gurr J.-R., Lin Y.-C., Ho I.-C., Jan K.-J., Lee T.-C. Induction of chromatid breaks and tetraploidy in Chinese hamster ovary cells by treatment with sodium arsenite during the G2 phase. Mutat. Res. 319:1993;135-142.
83. Huang R.N., Ho I.C., Yih L.H., Lee T.C. Sodium arsenite induces chromosome endoreduplication and inhibits protein phosphatase activity in human fibroblasts. Environ. Mol. Mutagen. 25:1995;188-196.
84. Kochhar T.S., Howard W., Hoffman S., Brammer-Carleton L. Effect of trivalent and pentavalent arsenic in causing chromosome alterations in cultured CHO cells. Toxicol. Lett. 84:1996;37-42.
85. Titenko-Holland N., Moore L.E. Measurement and characterization of micronuclei in exfoliated human cells by fluorescence in situ hybridization with a centromeric probe. Mutat. Res. 312:1994;39-59.
86. Fenech M., Crott J., Turner J., Brown S. Necrosis, apoptosis, cytostasis and DNA damage in human lymphocytes measure simultaneoulsy within the cytokineses-block micronucleus assay: description of the method and results for hydrogen peroxide. Mutagenesis. 14:1999;605-612.
87. Eastmond D.A., Tucker J.D. Kinetochore localization in micronucleated cytokinesis-blocked Chinese hamster ovary cells a new and rapid assay for identifying aneuploidy-inducing agents. Mutat. Res. 224:1989;517-525.
88. Wang Z., Rossman T.G. Stable and inducible arsenite resistance in Chinese hamster cells. Toxicol. Appl. Pharmacol. 118:1993;80-86.
89. Lee T.-C., Ho I.-C. Modulation of cellular antioxidant defense activities by sodium arsenite in human fibroblasts. Arch. Toxicol. 69:1995;498-504.
90. Schuliga M., Chouchane S., Snow E.T. Upregulation of glutatione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol. Sci. 70:2002;183-192.
91. Brambila E.M., Achanzar W.E., Qu W., Webber M.M., Waalkes M.P. Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione S-transferase. Toxicol. Appl. Pharmacol. 183:2002;99-107.
92. Vega L., Gonseblatt M.E., Ostrosky-Wegman P. Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected. Mutat. Res. 334:1995;365-373.
93. Ramirez P., Eastmond D.A., Laclette J.P., Ostrosky-Wegman P. Disruption of microtubule assembly and spindle formation for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutat. Res. 386:1997;291-298.
94. Huang S.C., Lee T.C. Arsenite inhibits mitotic division and perturbs spindle dynamics in HeLa S3 cells. Carcinogenesis. 19:1998;889-896.
95. Sciandrello G., Barbaro R., Caradonna F., Barbata G. Early induction of genetic instability and apoptosis by arsenic in cultured Chinese hamster cells. Mutagenesis. 17:2002;99-103.
96. Warner M.L., Moore L.E., Smtih M.T., Kalman D.A., Fanning E., Smith A.H. Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contamined water in Nevada. Cancer Epidemiol. Biomarkers Prevent. 3:1994;583-590.
97. Tian D., Ma H., Feng Z., Xia Y., Le X.C., Ni Z., Allen J., Collins B., Schreinemachers D., Mumford J.L. Analyses of micronuclei in exfoliated epithelial cells from individuals chronically exposed to arsenic via drinking water in inner Mongolia, China. J. Toxicol. Environ. Health. 64:2001;473-484.
98. Basu A., Mahata J., Roy A.K., Sarlar J.N., Poddar G., Nandi A., Sarkar P.K., Dutta P.K., Banerjee A., Das M., Ray K., Roychaudhury S., Natarajan A.T., Nilsson R., Giri A.K. Enhanced frequency of micronuclei in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat. Res. 516:2002;29-40.
99. Dulout F.N., Grillo C.A., Seoane A.I., Maderna C.R., Nilsson R., Vahter M., Darroudi F., Natarajan A.T. Chromosomal aberrations in peripheral blood lymphocytes from native Andean women and children from northwestern Argentina exposed to arsenic in drinking water. Mutat. Res. 370:1996;151-158.
100. Gonsebatt M.E., Vega L., Salazar A.M., Montero R., Guzman P., Blas J., Del Razo L.M., Garcia-Vargas G., Albores A., Cerbrian M.E., Kelsh M., Ostrosky-Wegman P. Cytogenetic effects in human exposure to arsenic. Mutat. Res. 386:1997;219-228.
101. Maki-Paakkanen J., Kurttio P., Paldy A., Pekkanen J. Association between the clastogenic effect in peripheral lymphocytes and human exposure to arsenic through drinking water. Environ. Mol. Mutagen. 32:1998;301-313.
102. Mahata J., Basu A., Ghoshal S., Sarkar J.N., Roy A.K., Poddar G., Nandy A.K., Banerjee A., Ray K., Natarajan A.T., Nilsson R., Giri A.K. Chromosomal aberrations and sister chromatid exchanges in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat. Res. 534:2003;133-143.
103. Smith A.H., Hopenhayn-Rich C., Warner M., Biggs M.L., Moore L., Smith M.T. Rationale for selecting exfoliated bladder cell micronuclei as potential biomarkers for arsenic genotoxicity. J. Toxicol. Environ. Health. 40:1993;223-234.
104. Wiencke J.K., Yager J.W. Specificity of arsenite in potentiating cytogenetic damage induced by the DNA crosslinking agent diepoxybutane. Environ. Mol. Mutagen. 19:1992;195-200.
105. Sordo M., Herrera L.A., Ostrosky-Wegman P., Rojas E. Cytotoxic and genotoxic effects of As, MMA, and DMA on leukocytes and stimulated human lymphosytes. Teratog. Carcinog. Mutagen. 21:2001;249-260.
106. Crossen P.E. Arsenic and SCE in human lymphocytes. Mutat. Res. 119:1983;415-419.
107. Rasmussen R.E., Menzel D.B. Variation in arsenic-induced sister chromatid exchange in human lymphocytes and lymphoblastoid cell lines. Mutat. Res. 386:1997;299-306.
108. P. Li, A.N. Uddin, Z. Liu, R. Mukhopadhyay, E.V. Komissarova, B.P. Rosen, T.G. Rossman, Variability in sensitivity to arsenite does not correlate with arsenic accumulation rate in normal human lymphoblasts. Mol. Cell. Biochem., 2003, in press.
109. Nordenson I., Beckman L. Is the genotoxic effect of arsenic mediated by oxygen free radicals? Hum. Hered. 41:1991;71-73.
110. Huang H., Huang C.F., Wu D.R., Jinn C.M., Jan K.Y. Glutathione as a cellular defence against arsenite toxicity in cultured Chinese hamster ovary cells. Toxicology. 79:1993;195-204.
111. Wang T.S., Huang H. Active oxygen species are involved in the induction of micronuclei by arsenite in XRS-5 cells. Mutagenesis. 9:1994;253-257.
112. Fan S.-R., Ho I.-C., Yeoh F.L.-F., Lin C.-J., Lee T.-C. Squalene inhibits sodium arsenite-induced sister chromatid exchanges and micronuclei in Chinese hamster ovary-K1 cells. Mutat. Res. 368:1996;165-169.
113. Kessel M., Liu S.X., Xu A., Santella R., Hei T.K. Arsenic induces oxidative DNA damage in mammalian cells. Mol. Cell. Biochem. 234-235:2002;301-308.
114. Cantoni O., Hussain S., Guidarelli A., Cattabeni F. Cross-resistance to heavy metals in hydrogen peroxide-resistant CHO cell variants. Mutat. Res. 324:1994;1-6.
115. Liu S.X., Atar M., Lippai I., Waldren C., Hei T.K. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. PNAS. 98:2001;1643-1648.
116. Wang T.S., Shu Y.F., Liu Y.C., Jan K.Y., Huang H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology. 121:1997;229-237.
117. Pi J., Yamauchi H., Kumagai Y., Sun G., Yoshida T., Aikawa H., Hopenhayn-Rich C., Shimojo N. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ. Health Perspect. 110:2002;331-336.
118. Ramos O., Carrizales L., Yanez L., Mejia J., Batres L., Ortiz D., Diaz-Barriga F. Arsenic increased lipid peroxidation in rat tissues by a mechanism independent of glutathione levels. Environ. Health Perspect. 103:1995;85-88.
119. Oya-Ohta Y., Kaise T., Ochi T. Induction of chromosomal aberrations in cultured human fibroblasts by inorganic and organic arsenic compounds and the different roles of glutathione in such induction. Mutat. Res. 357:1996;123-129.
120. Albores A., Koropatnick J., Cherian M.G., Zelazowski A.J. Arsenic induces and enhances rat hepatic metallothionein production in vivo. Chem.-Biol. Interact. 85:1992;127-140.
121. Romach E.H., Zhao C.Q., DelRazo L.M., Cebrian M.E., Waalkes M.P. Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol. Sci. 54:2002;500-508.
122. Liu J., Liu Y., Goyer R.A., Achanzar W., Waalkes M.P. Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals. Toxicol Sci. 55:2000;460-470.
123. E.I. Goncharova, T.G. Rossman, The antimutagenic effects of metallothionein may involve free radical scavenging, in: B. Sarkar (Ed.), Genetic Response to Metals, Marcel Dekker, New York, 1995, pp. 87-100.
124. Guyton K.Z., Xu Q.B., Holbrook N.J. Induction of the mammalian stress response gene GADD153 by oxidative stress: role of AP-1 element. Biochem. J. 314:1996;547-554.
125. Keyse S.M., Tyrrell R.M. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc. Natl. Acad. Sci. U.S.A. 85:1989;99-103.
126. Parrish A.R., Zheng X.U., Turney K.D., Younis H.S., Gandolfi A.J. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol. Sci. 50:1999;98-105.
127. Yih L.-H., Peck K., Lee T.-C. Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis. 23:2002;867-876.
128. Menzel D.B., Rasmussen R.E., Lee E., Meacher D.M., Said B., Hamadeh H., Vargas M., Greene H., Roth R.N. Human lymphocyte heme oxygenase 1 as a response biomarker to inorganic arsenic. Biochem. Biophys. Res. Commun. 250:1998;653-656.
129. Rea M.A., Gregg J.P., Qin Q., Phillips M.A., Rice R.H. Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis. 24:2003;747-756.
130. Zheng X.H., Watts G.S., Vaught S., Gandolfi A.J. Low-level arsenite induced gene expression in HEK293 cells. Toxicology. 187:2003;39-48.
131. Applegate L.A., Janscher P., Tyrell M. Induction of heme oxygenase: a general response to oxidative stress in cultured mammalian cells. Cancer Res. 51:1991;974-978.
132. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science. 235:1987;1043-1047.
133. Ryter S.W., Choi A.M. Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. Antioxid. Redox Signal. 4:2002;625-632.
134. Lee T.C., Ho I.C. Expression of heme oxygenase in arsenic-resistant human lung adenocarcinoma cells. Cancer Res. 54:1994;1660-1664.
135. Ho I.-C., Yih L.-H., Kao C.-Y., Lee T.-C. Tin-protoporphyrin potentiates arsenite-induced DNA strand breaks. Mutat. Res. 452:2000;41-50.
136. Bau D.-T., Wang T.-S., Chung C.-H., Wang A.S.S., Jan K.-Y. Oxidative DNA adducts and DNA-protein cross-links are the major DNA lesions induced by arsenite. Environ. Health Perspect. 110:2002;753-756.
137. Matsui M., Nishigori C., Toyokuni S., Takada J., Akaboshi M., Ishikawa M., Imamura S., Miyachi Y. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2″-deoxyguanosine in arsenic-related Bowen's disease. J. Invest. Dermatol. 113:1999;26-31.
138. Wang T.-S., Chung C.-H., Wang A.S.S., Bau D.-T., Samikkannu T., Jan K.-Y., Cheng Y.-M., Lee T.-C. Endonuclease III, formamidopyrimidine-DNA glycosylase, and proteinase K additively enhance arsenic-induced DNA strand breaks in human cells. Chem. Res. Toxicol. 15:2002;1254-1258.
139. Tchou J., Bodepuci V., Shibutani S., Antoshechkin I., Miller J., Grollman A.P., Johnson F. Substrate specificity of Fpg protein. Recognition and cleavage of oxidatively damaged DNA. J. Biol. Chem. 269:1994;15318-15324.
140. Hartmann A., Speit G. Effect of arsenic and cadmium on the persistence of mutagen-induced DNA lesions in human cells. Environ. Mol. Mutagen. 27:1996;98-104.
141. Gebel T., Birkenkamp P., Luthin S., Dunkelbert G. Arsenic(III), but not antimony(III), induced DNA-protein crosslinks. Anticancer Res. 18:1998;4253-4258.
142. Ide H. DNA substrates containing defined oxidative base lesions and their application to study substrate specificities of base excision repair enzymes. Prog. Nucleic Acid Res. Mol. Biol. 68:2001;207-221.
143. Li D., Morimoto K., Takeshita T., Lu Y. Formamidopyrimidine-DNA glycosylase enhances arsenic-induced DNA strand breaks in PHA-stimulated and unstimulated human lymphocytes. Environ. Health Perspect. 109:2001;523-526.
144. Smith K.R., Klei L.R., Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physical. Lung Cell. Mol. Physiol. 280:2001;L442-449.
145. Lynn S., Gurr J.-R., Lai H.-T., Yan K.-Y. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ. Res. 86:2000;514-519.
146. Pagano P.J. Vascular gp92phox: beyond the endothelium. Circ. Res. 87:2000;1-3.
147. Lynn S., Shiung N.-N., Gurr J.-R., Jan K.Y. Arsenite stimulates poly(ADP-ribosylation) by generation of nitric oxide. Free Radic. Biol. Med. 24:1998;442-449.
148. Gurr J.R., Liu F., Lynn S., Jan K.Y. Calcium-dependent nitric oxide production is involved in arsenite-induced micronuclei. Mutat. Res. 416:1998;137-148.
149. Liu R.H., Hotchkiss J.H. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat. Res. 339:1995;73-89.
150. Juedes M.J., Wogan G.N. Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Mutat. Res. 349:1996;51-61.
151. Liu F., Jan K.Y. DNA damage in arsenite- and cadmium-treated bovine aortic endothelial cells. Free Radic. Biol. Med. 28:2000;55-63.
152. Bunderson M., Coffin J.D., Beall H.D. Arsenic induced peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol. Appl. Pharmacol. 184:2002;11-18.
153. L.-H. Yih, T. Samikkannu, D.-T. Bau, S.-Y. Lin, K.-Y. Jan, Nitric oxide production by arsenite, Mutat. Res. 233 (2003) 173-182.
154. Wang T.-S., Hsu T.-T., Chung C.H., Wang A.S.S., Bau D.-T., Jan K.-Y. Arsenite induced oxidative DNA adducts and DNA-protein cross-links in mammalian cells. Free Radic. Biol. Med. 31:2001;321-330.
155. Mure K., Rossman T.G. Reduction of spontaneous mutagenesis in mismatch repair-deficient and proficient cells by dietary antioxidants. Mutat. Res. 480-481:2001;85-95.
156. Mure K., Uddin A., Lopez L.C., Styblo M., Rossman T.G. Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ. Mol. Mutagen. 41:2003;322-331.
157. Barrett J.C., Lamb P.W., Wang T.C., Lee T.C. Mechanism of arsenic-induced cell transformation. Biol. Trace Element Res. 21:1989;421-429.
158. Lee T.C., Tanaka N., Lamb W.P., Gilmer T.M., Barrett J.C. Induction of gene amplification by arsenic. Science. 241:1989;79-81.
159. Landolph J.R. Molecular mechanisms of transformation of C3H/10T1/2 C1 8 mouse embryo cells and diploid human fibroblasts by carcinogenic metal compounds. Environ. Health Perspect. 102:1994;119-125.
160. Achanzar W.E., Brambila E.M., Diwan B.A., Webber M.M., Waalkes M.P. Inorganic arsenite-induced malignant transformation of human prostate epitelial cells. J. Natl. Cancer Inst. 94:2002;1888-1891.
161. Zhao C.Q., Young M.R., A Diwan B., Coogan T.P., Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. U.S.A. 94:1997;10907-10912.
162. Chen H., Liu J., Zhao C.Q., Diwan B.A., Merick B.A., Waalkes M.P. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol. Appl. Pharmacol. 15:2001;260-268.
163. Takahashi M., Barrett J.C., Tsutsui T. Transformation by inorganic arsenic compounds of normal Syrian hamster embryo cells into a neoplastic state in which they become anchorage-independent and cause tumors in newborn hamsters. Int. J. Cancer. 99:2002;629-634.
164. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev./Genet. 3:2002;415-428.
165. Mass M.J., Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat. Res. 386:1997;263-277.
166. Zhong C.X., Mass M.J. Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol. Lett. 122:2001;223-234.
167. Okoji R.S., Yu R.C., Maronpot R.R., Froines J.R. Sodium arsenite administration via drinking water increases genome-side and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis. 23:2002;777-785.
168. McDorman E.W., Collins B.W., Allen J.W. Dietary folate deficiency enhances induction of micronuclei by arsenic in mice. Environ. Mol. Mutagen. 40:2002;71-77.
169. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:2000;168-174.
170. Lee Y.-W., Klein C.B., Kargacin B., Salnikow K., Kitahara J., Dowjat K., Zhitkovich A., Christic N.T., Costa M. Carcinogenic nickel sliences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol. Cell Biol. 15:1995;2547-2557.
171. J.-H. Li, Ph.D. Thesis, New York University, 1989.
172. Rossman T.G., Wolosin D. Differential susceptibility to carcinogen-induced amplification of SV40 and dhfr sequences in SV40-transformed human keratinocytes. Mol. Carcinog. 6:1992;203-213.
173. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D.
174. Chou W.-C., Hawkins A.L., Barrett J.F., Griffin C.A., Dang C.V. Arsenic inhibition of telomerase transcription leads to genetic instability. J. Clin. Invest. 108:2001;1541-1547.
175. Shay J.W., Baccchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer. 33:1997;787-791.
176. Blasco M.A., Lee H.-W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:1997;25-34.
177. Hackett J.A., Feldser D.M., Greider C.W. Telomere dysfunction increases mutation rate and genomic instability. Cell. 106:2001;275-286.
178. Rudolph K.L., Chang S., Lee H.-W., Blasco M., Gottlieb G., Greider C.W., DePinho R.A. Longevity, stress response, and cancer in aging telomerase deficient mice. Cell. 96:1999;1357-1365.
179. Maser R.S., DePinho R.A. Connecting chromosomes, crisis and cancer. Science. 297:2002;565-569.
180. Hackett J.A., Greider C.W. Balancing instability: dual role for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 21:2002;619-626.
181. Lundblad V. DNA ends: maintenance of chromosome termini versus repair of double strand breaks. Mutat. Res. 451:2000;227-240.
182. Cerone M.A., Londono-Vallejo J.A., Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum. Mol. Genet. 10:2001;1945-1952.
183. Sheel C., Schaefer K.L., Jauch A., Keller M., Wai D., Brinkschmidt C., van Valen F., Becker W., Dockhorn-Dworniczak B., Poremba C. Alternative lengthening of telomers is associated with chromosomal instability in osteosarcomas. Oncogene. 20:2001;3835-3844.
184. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., DePinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 400:2000;641-645.
185. O'Hagan R.C., Chang S., Maser R.S., Mohan R., Artandi S.E., Chin L., DePinho R.A. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell. 2:2002;149-155.
186. Rossman T.G. Role of metals in carcinogenesis. Effects of metals on mutagenesis and DNA repair. Environ. Health Perspect. 40:1981;189-195.
187. Lee T.-C., Huang R.Y., Jan K.Y. Sodium arsenite enhances the cytotoxicity clastogenicity and 6-thioguanine-resistant mutagenicity of ultraviolet light in Chinese hamster ovary cells. Mutat. Res. 148:1985;83-89.
188. Lee T.C., Wang-Wuu S., Huang R.Y., Lee K.C., Jan K.Y. Differential effects of the pre- and post-treatment of sodium arsenite on the genotoxicity of methylmethanesulfonate in Chinese hamster ovary cells. Cancer Res. 46:1986;1854-1857.
189. Lee T.-C., Lee K.C., Tseng Y.J., Huang R.Y., Jan K.Y. Sodium arsenite potentiates the clastogenicity and mutagenicity of DNA crosslinking agents. Environ. Mol. Mutagen. 8:1986;119-128.
190. Yang J.L., Chen M.F., Wu C.W., Lee T.C. Posttreatment with sodium arsenite alters the mutation spectrum induced by ultraviolet light irradiation in Chinese hamster ovary cells. Environ. Mol. Mutagen. 20:1992;156-164.
191. Jha A.N., Noditi M., Nilsson R., Natarajan A.T. Genotoxic effects of sodium arsenite on human cells. Mutat. Res. 284:1992;215-221.
192. Hartwig A., Groblinghoff U.D., Beyersmann D., Natarajan A.T., Filon R., Mullenders L.H.F. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis. 18:1997;399-405.
193. Li J.-H., Rossman T.G. Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. Mol. Toxicol. 2:1989;1-9.
194. Hu Y., Su L., Snow E.T. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat. Res. 408:1998;203-218.
195. Lynn S., Lai H.T., Gurr J.-R., Jan K.Y. Arsenite retards DNA strand break rejoining by inhibiting DNA ligation. Mutagenesis. 12:1997;353-358.
196. Asmuss M., Mullenders L.H., Eker A., Hartwig A. Differential effects of toxic metal compounds on the activities of Fpg and XPA, two zinc finger proteins involved in DNA repair. Carcinogenesis. 21:2000;2097-2104.
197. Canitrot Y., Frechet M., Servant L., Cazaux C., Hoffman J.S. Overexpression of DNA polymerase beta: a genomic instability enhancer process. FASEB J. 13:1999;1107-1111.
198. Yamada N.A., Farber R.A. Induction of a low level of microsatellite instability by overexpression of DNA polymerase b. Cancer Res. 62:2002;6061-6064.
199. Bergoglio V., Pillaire M.J., Lacroix-Triki M., Raynaud-Messina B., Canitrot Y., Bieth A., Gares M., Wright M., Delsol G., Loeb L.A., Cazaux C., Hoffman J.S. Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis. Cancer Res. 15:2002;3511-3514.
200. Kunkel T.A., Bebenek K. DNA replication fidelity. Annu. Rev. Biochem. 69:2000;497-529.
201. Hamadeh H.K., Trouba K.J., Amin R.P., Afshari C.A., Germolec D. Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci. 69:2002;306-316.
202. Yager J.W., Wiencke J.K. Inhibition of poly(ADP-ribose) polymerase by arsenite. Mutat. Res. 386:1997;345-351.
203. Hartwig A., Pelzer A., Asmuss M., Burkle A. Very low concentrations of arsenite suppress poly(ADP-ribosyl)ation in mammalian cells. Int. J. Cancer Int. J. Cancer. 104:2003;1-6.
204. Bürkle A. Physiology and pathophysiology of poly(ADP-rbosyl)ation. BioEssays. 23:2001;795-806.
205. Pleschke J.M., Kleczkowska H.E., Strohm M., Althaus F.R. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J. Biol. Chem. 29:2000;40974-40980.
206. Tsutsumi M., Masutani M., Nozaki T., Kusuoka O., Tsujiuchi T., Nakagama H., Suzuki H., Konishi Y., Sugimura T. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity. Carcinogenesis. 22:2001;1-3.
207. Beneke R., Geisen C., Zevnik B., Bauch T., Müller W.-U., Küpper J.-H., Möröy T. DNA excision repair and DNA damage-induced apoptosis are linked to poly(ADP-ribosyl)ation but have different requirements for p53. Mol. Cell Biol. 20:2000;6695-6703.
208. Pirrotta V. Puffing with PARP. Science. 299:2003;528-529.
209. Simbulan-Rosenthal C.M., Ly D.H., Rosenthal D.S., Konopka G., Luo R., Wang Z.-Q., Schultz P.G., Smulson M.E. Misregulation of gene expression in primary fibroblasts lacking poly (ADP-ribose) polymerase. PNAS. 21:2000;11274-11279.
210. Ziegler M., Oei S.L. A cellular survival switch: poly(ADP-ribosyl)ation stimulates DNA repair and silences transcription. BioEssays. 23:2001;543-548.
211. Smith S., de Lange T. Tankyrase promotes telomere elongation in human cells. Current Biol. 10:2000;1299-1302.
212. Rouse J., Jackson S.P. Interfaces between the detection, signaling and repair of DNA damage. Science. 297:2002;547-551.
213. Alarcon-Vargas D., Ronai Z. p53 Mdm2-the affair that never ends. Carcinogenesis. 23:2002;541-547.
214. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damge. Cancer Res. 51:1991;6304-6311.
215. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., Reed J.C. Tumor suppresser p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
216. Salazar A.M., Ostrosky W.P., Menendez D., Miranda E., Garcia C., Rojas E. Induction of p53 protein expression by sodium arsenite. Mutat. Res. 381:1997;259-265.
217. Yih L.H., Lee T.C. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res. 60:2000;6346-6352.
218. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
219. Hamadeh H.K., Vargas M., Lee E., Menzel D.B. Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. Biochem. Biophys. Res. Commun. 263:1999;446-449.
220. Lehman T.A., Modali R., Boukamp P., Stanek J., Bennett W.P., Welsh A., Metcalf R.A., Stampfer M.R., Fusenig N., Rogan E.M., Harris C.C. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis. 14:1993;833-839.
221. Hainaut P. The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr. Opin. Oncol. 7:1995;76-82.
222. Germolec D., Spalding J., Yu H.-S., Chen G.S., Simeonova P.O., Humble M.C., Bruccoleri A., Boorman G.A., Foley J.F., Yoshida T., Luster M.I. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153:1998;1775-1785.
223. Trouba K.J., Wauson E.M., Vorce R.L. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol. Appl. Pharmacol. 164:2000;161-170.
224. Hartwig A., Asmuss M., Ehleben I., Herzer U., Kostelac D., Pelzer A., Schgwerdtle T., Burkle A. Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ. Health Perspect. 110:2002;797-799.
225. Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55:1995;4420-4424.
226. Yu Y., Li C.-Y., Little J.B. Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblase cells. Oncogene. 14:1997;1661-1667.
227. Reznikoff C.A., Belair C., Savelieva E., Zhai Y., Pfeifer K., Yeager T., Thompson K.J., DeVries S., Bindley C., Newton M.A. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-immortalized human uroepithelial cells. Genes Dev. 8:1994;2227-2240.
228. Tlsty T.D., Brot A., Gualberto A., Hall I., Hess S., Hixon M., Kuppuswamy D., Romanov S., Sage M., White A. Genomic instability and cancer. Mutat. Res. 337:1995;1-7.
229. Merwin J.R., Mustacich D.J., Muller E.G.D., Pearson G.D., Merrill G.F. Reporter gene transactivation by human p53 is inhibited in thioredoxin reductase null yeast by a mechanism associated with thioredoxin oxidation and independent of changes in the redox state of glutathione. Carcinogenesis. 23:2002;1609-1615.
230. Francesconi K.A., Tanggaar R., McKenzie C.J., Goessler W. Arsenic metabolites in human urine after injection of an arsenosugar. Clin. Chem. 48:2002;92-101.
231. Buchet J.P., Lauwerys R., Roels H. Comparison of the urinary excretion of arsenic metabolites after a single dose of sodium arsenite, monomethylarsonate or dimethylarsinate in man. Int. Arch. Occup. Environ. Health. 48:1981;71-79.
232. Kenyon E.M., Hughes M.F. A concise review of the toxicity and carcinogenicity of dimethylarsinic acid. Toxicology. 160:2001;227-236.
233. Wanibuchi H., Yamamoto S., Chen H., Yoshida G., Endo G., Hon T., Fuykushima S. Promoting effects of dimethylarsinic acid on N-butyl-N-(4- hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats. Carcinogenesis. 17:1996;2435-2439.
234. Yamanaka K., Hasegawa A., Sawamura R., Okada S. Dimethylated arsenics induce DNA strand breaks in lung via the production of active oxygen in mice. Biochem. Biophys. Res. Commun. 165:1989;43-50.
235. Arnold L.L., Cano M., John M.St., Eldan M., van Gemert M., Cohen S.M. Effects of dietary dimethylarsinic acid on the urine and urothelium of rats. Carcinogenesis. 10:1999;2171-2179.
236. Yamanaka K., Hasegawa A., Sawamura R., Okada S. Cellular response to oxidative damage in lung induced by the administration of dimethylarsinic acid, a major metabolite of inorganic arsenics, in mice. Toxicol. Appl. Pharmacol. 108:1991;205-213.
237. Brown J.L., Kitchin K.T. Arsenite, but not cadmium, induces ornithine decarboxylase and heme oxygenase activity in rat liver: relevance to arsenic carcinogenesis. Cancer Lett. 98:1996;227-231.
238. Yamanaka K., Ohtsubo K., Hasegawa A., Hayashi H., Ohji H., Kanisawa M., Okada S. Exposure to dimethylarsinic acid, a main metabolite of inoranic arsenics, strongly promotes tumorigenesis initiated by 4-nitroquinoline 1-oxide in the lungs of mice. Carcinogenesis. 17:1996;767-770.
239. Yamanaka K., Katsumata K., Ikuma K., Hasegawa A., Nakano M., Okada S. The role of orally administered dimethylarsinic acid, a main metabolite of inorganic arsenics, in the promotion and progression of UVB-induced skin tumorigenesis in hairless mice. Cancer Lett. 152:2000;79-85.
240. Hayashi H., Kanisawa M., Yamanaka K., Ito T., Udada N., Ohji H., Okudela K., Okada S., Kitamura H. Dimethylarsenic acid, a main metabolite of inorganic arsenics, has tumorigenicity and progression effects in the pulmonary tumors of A/J mice. Cancer Lett. 125:1998;83-88.
241. Yamanaka K., Takabayashi F., Mizoi M., An Y., Hasegawa A., Okada S. Oral exposure of dimethylarsinic acid, a main metabolite of inorganic arsenics, in mice leads to an increase in 8-oxo-2'-deoxyguanosine level, specifically in the target organs for arsenic carcinogenesis. Biochem. Biophys. Res. Commun. 14:2001;66-70.
242. Wei M., Wanibuchi H., Yamamoto S., Li W., Fukushima S. Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis. 20:1999;1873-1876.
243. Wei M., Wanibuchi H., Morimura K., Iwai S., Yoshida K., Endo G., Nakae D., Fukushima S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis. 23:2002;1387-1397.
244. A. Leonard, Arsenic, in: E. Merian (Ed.), Metals and their Compounds in the Environment, Verlagsgesellschaft Publishers Inc., New York, 1991, pp. 751-774.
245. Yamanaka K., Hoshino M., Okamoto M., Sawamura R., Hssegawa A., Okada S. Induction of DNA damage by dimethylarsine, a metabolite or inorganic arsenics, is for the major part likely due to its peroxyl radical. Biochem. Biophys. Res. Commun. 16:1990;58-64.
246. Yamanaka K., Okada S. Induction of lung-specific DNA damage by metabolically methylated arsenics via the production of free radicals. Environ. Health Perspect. 102:1994;37-40.
247. Cohen S.M., Arnold L.L., Uzvolgyi E., Cano M., John M.St., Yamamoto S., Lu X., Le X.C. Possible role of dimethylarsinous acid in dimethylarsinic acid-induced urothelial toxicity and regeneration in the rat. Chem. Res. Toxicol. 15:2002;1150-1157.
248. Vigayaraghavan M., Wanibuchi H., Karim R., Yamamoto S., Masuda C., Nakae D., Konishi Y., Fukushima S. Dimthylarsinic acid induces 8-hydroxy-2′- deoxyguanosine formation in the kidney of NCI-black-reiter rats. Cancer Lett. 165:2001;11-17.
249. Kashiwada E., Kuroda K., Endo G. Aneuploidy induced by dimethylarsinic acid in mouse bone marrow cells. Mutat. Res. 413:1998;33-38.
250. Yamanaka K., Hayashi H., Tachikawa M., Kato K., Hasegawa A., Oku N., Okada S. Metabolic methylation is a possible genotoxicity-enhancing process of inorganic arsenics. Mutat. Res. 394:1997;95-101.
251. Noda Y., Suzuka T., Kohara A., Hasegawa A., Yotsuyanagi T., Hauashi M., Sofuni T., Yamanaka K., Okada S. In vivo genotoxicity evaluation of dimethylarsinic acid in mutamouse. Mutat. Res. 513:2002;205-212.
252. Mass M.J., Tennant A., Roop B.C., Cullen W.R., Styblo M., Thomas D.J., Kligerman A.D. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 14:2001;355-361.
253. Nesnow S., Roop B.C., Lambert G., Kadiiska M.B., Mason R.P., Cullen W.R., Mass M.J. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem. Res. Toxicol. 15:2002;1627-1634.
254. Ahmad S., Kitchin K.T., Cullen W.R. Plasmid DNA damage caused by methylated arsenicals, ascorbic acid and human liver ferritin. Toxicol Lett. 133:2002;47-57.
255. Peng B., Sharma R., Mass M.J., Kligerman A.D. Induction of genotoxic damage is not correlated with the ability to methylate arsenite in vitro in the leukocytes of 4 mammailan species. Environ. Mol. Mutagen. 39:2002;323-332.
256. Gregus Z., Gyurasics A., Csanaky I. Billary and urinary excretion of inorganic arsenic: monomethylarsonous acid as a major biliary metabolite in rats. Toxicol. Sci. 56:2000;18-25.
257. Aposhian G.V., Gurzau E.S., Le X.C., Gurzau A., Healy S.M., Lu X., Ma M., Yip L., Zakharyan R.A., Maiorino R.M., Dart R.C., Tircus M.G., Gonzalez-Ramirez D., Morgan D.L., Avran D., Aposhian M.M. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 13:2000;693-697.
258. Mandal B.K., Ogra Y., Suzuki K.T. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem. Res. Toxicol. 14:2001;371-378.
259. Sakurai T., Qu W., Sakurai M.H., Waalkes M.P. A major human arsenic metabolite, dimethylarsinic acid, requires reduced glutathione to induce apoptosis. Chem. Res. Toxicol. 15:2002;629-637.
260. Cohen S.M., Ellwein L.B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51:1991;6493-6505.
261. Schwartz M.A., Assoian R.K. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J. Cell Sci. 114:2001;2553-2560.
262. Simeonova P.P., Wang S., Toriuma W., Kommineni V., Matheson J., Unimye N., Kayama F., Harki D., Ding M., Vallyathan V., Luster M.I. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res. 60:2000;3445-3453.
263. Germolec D.R., Yoshida T., Gaido K., Wilmer J.L., Simeonova P.P., Kayama F., Burleson F., Dong W., Lange R.W., Luster M.I. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol. 141:1996;308-318.
264. Barchowsky A., Klei L.R., Dudek E.J., Swartz H.M., James P.E. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 27:1999;1405-1412.
265. van Wijk R., Welters M., Souren J.E.M., Ovelgonne H., Wiegant F.A.C. Serum-stimulated cell cycle progression and stress protein synthesis in C3H10T1/2 fibroblasts treated with sodium arsenite. J. Cell. Physiol. 155:1993;265-272.
266. Dong Z. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ. Health Perspect. 110:2002;757-759.
267. Yang C., Frenkel K. Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: implications in carcinogenesis. J. Environ. Pathol. Toxicol. Oncol. 21:2002;331-342.
268. G.K. Harris, X. Shi, Signaling by carcinogenic metals and metal-induced reactive oxygen species, Mutat. Res. 233 (2003) 183-200.
269. Chen W., Martindale J.L., Holbrook N.J., Liu Y. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc. Mol. Cell Biol. 18:1998;5178-5188.
270. Simeonova P.P., Wang S., Hulderman T., Luster M.I. c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. J. Biol. Chem. 277:2002;2945-2950.
271. Sherr C.J. The pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
272. Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
273. Ho A., Dowdy S.F. Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes. Curr. Opin. Genet. Dev. 12:2002;47-52.
274. Page K., Li J., Wang Y., Kartha S., Pestell R.G., Hershenson M.B. Regulation of cyclin D(1) expression and DNA synthesis by phosphatidylinositol 3-kinase in airway smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 23:2000;436-443.
275. Gille H., Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J. Biol. Chem. 274:1999;22033-22040.
276. Kandal E.S., Skeen J., Majewski N., Di Cristofano A., Pandolfi P.P., Feliciano C.S. Activation of Akt/protein kinase overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol. Cell Biol. 22:2002;7831-7841.
277. Souza K., Maddock D.A., Zhang Q., Chen J., Chiu C., Mahta S., Wan Y. Arsenite activation of P13K/AKT cell survival pathway is mediated by p38 in cultured human keratinocytes. Mol. Med. 7:2001;767-772.
278. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene. 20:2001;2390-2400.
279. Kaltreider R.C., Pesce C.A., Ihnat M.A., Lariviere J.P., Hamilton J.W. Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding. Mol. Carcinog. 25:1999;219-229.
280. Simeonova P.P., Wang S., Kashon M.L., Kommineni C., Crecelius E., Luster M.I. Quantitative relationship between arsenic exposure and AP-1 activity in mouse urinary bladder epithelium. Toxicol. Sci. 60:2001;279-284.
281. Huang C., Li J., Ding M., Wang L., Shi X., Castranova V., Vallyathan V., Ju G., Costa M. Arsenic-induced NFkB transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol. Cell. Biochem. 222:2001;29-34.
282. Yang J., Yu Y., Duerksen-Hughes P.J. Protein kinases and their involvement in the cellular responses to genotoxic stress. Mutat. Res. 543:2003;31-58.
283. Barchowsky A., Dudek E.J., Treadwell M.D., Wetterhahn K.E. Arsenic induces oxidant stress and NF-KappaB activation in cultured aortic endothelial cells. Free. Radic. Biol. Med. 21:1996;783-790.
284. Simile M.M., Pascale R., De Miglio M.R., Nufris A., Daino L., Seddaiu M.A., Gaspa L., Feo F. Correlation between S-adenosyl-L-methionine content and production of c-myc, c-Ha-ras, and c-Ki-ras mRNA transcripts in the early stages of rat liver carcinogenesis. Cancer Lett. 79:1994;9-16.
285. Shimizu M., Hochadel J.F., Fulmer B.A., Waalkes M.P. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol. Sci. 45:1998;204-211.
286. Liu C.H., Zhao C.Q., Diwan B.A., Merrick B.A., Waalkes M.P. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol. Appl. Pharmacol. 15:2001;260-268.
287. Mass-Szabowski N., Szabowski A., Stark H.J., Andrecht S., Kolbus A., Schorpp-Kistner M., Angel P., Fusenig N.E. Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation. J. Invest. Dermatol. 116:2001;816-820.
288. Trouba K.J., Wauson E.M., Vorce R.L. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes. Toxicol. Appl. Pharmacol. 168:2000;25-35.
289. Wauson E.M., Langan A.S., Vorce R.L. Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. Toxicol. Sci. 65:2002;211-219.
290. Kachinskas D.J., Qin Q., Phillips M.A., Rice R.H. Arsenite suppression of human keratinocyte programming. Mutat. Res. 386:1997;253-261.
291. Jessen B.A., Qin Q., Phillips M.A., Phillips D.L., Rice R.H. Keratinocyte differentiation marker suppression by arsenic: mediation by AP1 response elements and antagonism by tetradecanoylphorbol acetate. Toxicol. Appl. Pharmacol. 174:2001;302-311.
292. Kirkpatrick D.S., Dale K.V., Catania J.M., Gandollfi A.J. Low-level arsenite causes accumulation of ubiquitinated proteins in rabbit renal cortical slices and HEK293 cells. Toxicol Appl. Pharmacol. 186:2003;101-109.
293. Rossman T.G., Wang Z. Expression cloning for arsenite-resistance resulted in isolation of tumor-suppressor fau cDNA: possible involvement of the ubiquitin system in arsenic carcinogenesis. Carcinogenesis. 20:1999;311-316.
294. Rossman T.G., Visalli M.A., Komissarova E.V. fau and its ubiquitin-like domain (FUB1) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence. Oncogene. 22:2003;1817-1821.
295. Kaltreider R.C., Davis A.M., Lariviere J.P., Hamilton J.W. Arsenic alters the function of the glucocorticoid receptor as a transcription factor. Environ. Health Perspect. 109:2001;245-251.
296. Budunova I.V., Carbajal S., Kang H., Viaje A., Slaga T.J. Altered glucocorticoid receptor expression and function during mouse skin carcinogenesis. Mol. Carcinog. 18:1997;177-185.
297. Lansdown A.B.G. Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit. Rev. Toxicol. 25:1995;397-462.
298. Tice R.R., Yager J.W., Andrews P., Crecelius E. Effect of hepatic methyl donor status on urinary excretion and DNA damage in B6C3F1 mice treated with sodium arsenite. Mutat. Res. 386:1997;315-334.
299. Salim E.I., Wanibuchi H., Morimura K., Wei M., Mitsuhashi M., Yoshida K., Endo G., Fukushima S. Carcinogenicity of dimethylarsinic acid in p53 heterozygous knockout and wild-type C57BL/6J mice. Carcinogenesis. 24:2003;335-342.